Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of Concerns

Dominik Alexander Rothen; Pascal Siegfried Krenger; Aleksandra Nonic; Ina Balke; Anne-Cathrine Vogt; Xinyue Chang; Alessandro Manenti; Fabio Vedovi; Gunta Resevica; Senta Walton; Andris Zeltins; Emmanuele Montomoli; Monique Vogel; Martin Fabian Bachmann; Mona Omar Mohsen.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-459749

Documentos relacionados

  1. Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern.
  2. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization.
  3. Protective neutralizing epitopes in SARS-CoV-2.
  4. Precise control of digital dental unit to reduce aerosol and splatter production: new challenges for future epidemics.
  5. The humoral response and antibodies against SARS-CoV-2 infection.
  6. T Cell Responses to SARS-CoV-2.
  7. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease.
  8. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
  9. Circular RNA vaccines against SARS-CoV-2 and emerging variants.
  10. A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2.